Hepatic Encephalopathy Market Size to Exceed USD 658.1 Mn by 2032

The Hepatic Encephalopathy Market, estimated at USD 449.4 Mn in 2025, is expected to exhibit a CAGR of 5.6% and reach USD 658.1 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

An increase in the prevalence of liver cirrhosis is expected to drive the growth of global hepatic encephalopathy market over the forecast period. For instance, according to an article published by National Centre for biotechnology information, in November 2025, the incidence of cirrhosis was assessed at 23.2 per 100,000 person-years, with a higher rate of 30.5 in men and 16.4 in women.

Global Hepatic Encephalopathy Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic. But the COVID-19 market has continued to have a positive effect overall influence on chronic illness management.

Liver injury has been reported as a common manifestation with unclear clinical significance. The potential mechanisms of liver injury in COVID-19 include direct damage by the virus (based on the presence of the ACE2 receptor in the liver), psychological stress, systemic inflammatory response, drug-induced liver injury, and the progression of pre-existing liver diseases, i.e., from simple fatty liver to steatohepatitis. Although COVID-19 patients with chronic liver disease (CLD) have been deemed to be at an increased risk for serious illness in many studies, little is known about the impact of CLD on the natural history and outcome of COVID-19

The pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. For instance, according to U.S. Food and Drug Administration (FDA), September, 2025, in the U.S. alone, there were 148 antibiotic shortages from 2001 to 2013, and a recent penicillin shortage affected at least 39 countries throughout Europe, the Americas, and Asia Pacific. As of June 29, 2025, 10.5% of all drug shortages listed by the U.S. FDA were antibiotics.

Furthermore, according to the same source the long-term usage of protective clothing and contacting disinfectants can disrupt the skin barrier, increasing the risk for infections and autoimmune conditions.

Global Hepatic Encephalopathy Market: Key Developments

In October 2025 , SC Pharmaceuticals, is a pharmaceutical company focused on developing and commercializing innovative solutions to enhance the potential of outpatient care, announced has FUROSCIX (Furosemide Injection) is the first and only Food and Drug Application (FDA)-approved subcutaneous loop diuretic that balance may precipitate hepatic encephalopathy and coma. This factors boost the market growth in upcoming year.

In December 2025, GENFIT, a biotechnology company, and Ipsen, a medium-sized biopharmaceutical company, entered into agreement for Elafibranor, a Phase III. This agreement helps Ipsen to develop, manufacture and commercialize GENFIT’s investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC)

Browse 42 Market Data Tables and 35 Figures spread through 210 Pages and in-depth TOC on “Global Hepatic Encephalopathy Market”- Forecast to 2032, by Drug Class (Antibiotics, Laxatives, L-ornithine L-aspartate and others), by Route of administration (Oral, Intravenous, Rectal, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596

Key Takeaways of the Global Hepatic Encephalopathy Market:

• The global hepatic encephalopathy market is expected to exhibit a CAGR of 5.6% during the forecast period due to the increase in the new therapies by key market player. For instance, in September 2025, according to American Association for the Study of Liver Diseases (AASLD) guidelines for Hepatic encephalopathy management recommend neomycin as an alternative for the treatment of overt HE.
• Among route of administration, injectable segment is estimated to hold a dominant position in the global hepatic encephalopathy market over the forecast period. Increase in demand for injectable due to efficacy of products is likely drive the growth of segment
• Among distribution channel, in hospital pharmacies segment is attributed to hold a dominant position in the global hepatic encephalopathy market over the forecast period, owing to the increase in chronic illness patient visit to hospital. This factor influence the growth of segment.
• ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V, Lupin Limited., Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB., Norgine B.V., Abbott Laboratories, QR Science and Technology development Co.